Antibody-based HIV-1 vaccines: recent developments and future directions.
about
The spread, treatment, and prevention of HIV-1: evolution of a global pandemicTherapeutic antibodies, vaccines and antibodyomesThe aftermath of the Merck's HIV vaccine trialOrganizing the HIV vaccine development effortMolecular architecture of native HIV-1 gp120 trimersAutoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environmentsCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitopeThe cat and mouse of HIV-1 antibody escape.Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirsHIV-1 vaccine development after STEP.A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays.Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions.Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigsDifferential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production.HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodiesInternational technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.Critical issues in mucosal immunity for HIV-1 vaccine development.Comparison on virulence and immunogenicity of two recombinant vaccinia vaccines, Tian Tan and Guang9 strains, expressing the HIV-1 envelope gene.Challenges in the development of an HIV-1 vaccine.AFM force measurements of the gp120-sCD4 and gp120 or CD4 antigen-antibody interactionsGenetic imprint of vaccination on simian/human immunodeficiency virus type 1 transmitted viral genomes in rhesus macaquesComplement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDSAntigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccineWhat Has 30 Years of HIV Vaccine Research Taught Us?Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheetHeterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assaysInfluenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines.Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustionCharacterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies.Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals.A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: potential impact on CTL epitopesPrevention of the sexual transmission of HIV-1: preparing for success.Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strainPathogenic mechanisms of B-lymphocyte dysfunction in HIV disease
P2860
Q22241890-AA9319E2-721F-4BFD-9A0E-D65BA8A3C14BQ24599662-B61DB619-CA7D-4EF0-AC49-2F9C23A6A93EQ24654458-60267768-BEC5-465A-B71E-69E7F54AF57BQ27026502-56E726C8-247E-4E0A-8172-A44A35DE3708Q27651385-B3B30BB0-A397-4761-AC5C-968556F07D50Q27680125-6966C44C-41D6-461D-99CC-DBCD9176989FQ28476693-7414C928-44B6-4BA2-A655-B7F859F81FE6Q33348658-5D6247B6-BA89-4039-A27C-BD2F3B679256Q33417195-40565C44-2239-4430-9B6D-918DB9A0D756Q33504607-D09013CB-94FB-4E38-86E0-66485CE2BB01Q33571825-EAD3C41D-E244-4E79-85E9-1CE61E21044FQ33604776-397938F3-09AF-4AD8-B1C6-2BEF17EBFF55Q33642318-0DF8153A-CFDD-48C8-9773-1EC80F4A5CF4Q33653774-F7FFAEF0-7E96-4CC2-8032-323502A57F7BQ33676520-B9C9C475-A9E3-47BC-964B-A46AC9E6384FQ33725679-AA4F1320-12DF-4B8F-ADD6-940284B2EE30Q33827798-E81928E7-4755-4750-9819-A6A835AF26EEQ33869882-D0E7C17A-26FA-422A-9A0F-85C005B1BD1DQ34150070-8E3E3485-A702-4CA4-87FF-C5F1031A1DA2Q34290973-BD8D68EA-A932-4DAA-A280-C67531D2AFE0Q34357068-2AC20F22-2E51-4E69-B786-7CE8BD983624Q34459985-BCC88141-C645-4E96-99CF-94006981E283Q34471962-C9595423-9B56-4B83-BE90-05F65A1D3958Q34657290-E0BC9179-67CC-475D-9FFD-993058EE06E0Q34862368-AE9A648C-9BAC-4C6E-B7E7-4C7A3151630FQ34962907-96806686-8C26-4C78-944B-530ECD611164Q35097510-0FEA7D44-1FCD-4AA0-81A8-E4EA9B44F1B4Q35175380-42E927F5-CFD5-4B73-89F5-6215B2D053B1Q35826634-4114ACFD-2C4D-4BE0-800C-21529BE93707Q36057328-F3FD388E-2448-4075-9DB5-DC574E4E6770Q36162593-BB1FF37B-91A8-420A-8795-3C094AF0C569Q36363866-E7DA8FB2-2097-4649-BBE4-70192A6FCD92Q36432748-1E03B1BB-1AA7-4AC3-B811-96A58930E93EQ36545994-0165B9CE-D493-41BE-932B-AE9109FCF829Q36742268-D2BE2411-7B95-40A1-BF8A-394DB1B98AFBQ36851936-FD328301-4DF8-478A-829F-6715A7025BE7Q36908259-4E1E0E6A-356B-4E51-B1F9-E49B63D80999Q36975282-CF7DC2A1-F719-4C22-B484-46125A89D6D6Q37176547-CD0291A3-E9EB-4AC4-9D40-F32994576F51Q37189179-BA6A75F8-A0F5-436B-9737-3DABE8C6877B
P2860
Antibody-based HIV-1 vaccines: recent developments and future directions.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antibody-based HIV-1 vaccines: recent developments and future directions.
@en
Antibody-based HIV-1 vaccines: recent developments and future directions.
@nl
type
label
Antibody-based HIV-1 vaccines: recent developments and future directions.
@en
Antibody-based HIV-1 vaccines: recent developments and future directions.
@nl
prefLabel
Antibody-based HIV-1 vaccines: recent developments and future directions.
@en
Antibody-based HIV-1 vaccines: recent developments and future directions.
@nl
P2093
P2860
P50
P1433
P1476
Antibody-based HIV-1 vaccines: recent developments and future directions.
@en
P2093
Jorge Flores
José Esparza
Working Group convened by the Global HIV Vaccine Enterprise
P2860
P356
10.1371/JOURNAL.PMED.0040348
P407
P577
2007-12-01T00:00:00Z